Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model

Toxicology and Applied Pharmacology

Volumn 266, Issue 2, 2013, Pages 233-244

  Kurundkar, Deepali ^a   Srivastava, Ritesh K ^a   Chaudhary, Sandeep C ^a   Ballestas, Mary E ^b   Kopelovich, Levy ^c   Elmets, Craig A ^a   Athar, Mohammad ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Histone deacetylase inhibitors; MTOR; Skin cancer; Vorinostat

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN D2; CYCLIN E; CYCLINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 7; HISTONE H3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPIDERMOID SQUAMOUS CELL CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTONE ACETYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL SURVIVAL; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOCOMPROMISED HOST; MICE; MICE, NUDE; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 84871822817     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.11.002     Document Type: Article

References (42)

1. Aberg F., Isoniemi H., Hockerstedt K. Long-term results of liver transplantation. Scand. J. Surg. 2011, 100:14-21.
2. Alam M., Brown R.N., Silber D.H., Mullen G.M., Feldman D.S., Oren R.M., Yancy C.W. Increased incidence and mortality associated with skin cancers after cardiac transplant. Am. J. Transplant. 2011, 11:1488-1497.
3. Bi G., Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell. Mol. Immunol. 2006, 3:285-290.
4. Bruzzese F., Leone A., Rocco M., Carbone C., Piro G., Caraglia M., Di Gennaro E., Budillon A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 2011, 9:2378-2390.
5. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60:5165-5170.
6. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269:7-17.
7. Carroll R.P., Ramsay H.M., Fryer A.A., Hawley C.M., Nicol D.L., Harden P.N. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am. J. Kidney Dis. 2003, 41:676-683.
8. Chang C.C., Lin B.R., Chen S.T., Hsieh T.H., Li Y.J., Kuo M.Y. HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma. J. Oral Pathol. Med. 2011, 40:567-575.
9. Chaudhary S.C., Kurundkar D., Elmets C.A., Kopelovich L., Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway(†). Photochem. Photobiol. 2012, 5:1149-1156.
10. Chou C.W., Wu M.S., Huang W.C., Chen C.C. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 2011, 6:e18087.
11. Dashwood R.H., Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol. 2007, 17:363-369.
12. Diepgen T.L., Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 2002, 61:1-6.
13. Einspahr J.G., Calvert V., Alberts D.S., Curiel-Lewandrowski C., Warneke J., Krouse R., Stratton S.P., Liotta L., Longo C., Pellicani G., Prasad A., Sagerman P., Bermudez Y., Deng J., Bowden G.T., Petricoin E.F. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev. Res. (Phila.) 2012, 5:403-413.
14. Ellis L., Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 2010, 3:2411-2469.
15. Erlich R.B., Kherrouche Z., Rickwood D., Endo-Munoz L., Cameron S., Dahler A., Hazar-Rethinam M., de Long L.M., Wooley K., Guminski A., Saunders N.A. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br. J. Cancer 2012, 106:107-115.
16. Euvrard S., Kanitakis J., Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med. 2003, 348:1681-1691.
17. Facchetti F., Previdi S., Ballarini M., Minucci S., Perego P., LaPorta C.A. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004, 9:573-582.
18. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., Blenis L. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24:200-216.
19. Giommarelli C., Zuco V., Favini E., Pisano C., Dal Piaz F., De Tommasi N., Zunino F. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell. Mol. Life Sci. 2010, 67:995-1004.
20. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 10:1317-1322.
21. Iglesias-Linares A., Yanez-Vico R.M., Gonzalez-Moles M.A. Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. Oral Oncol. 2010, 46:323-329.
22. Karam M., Legay C., Auclair C., Ricort J.M. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp. Cell Res. 2012, 318:558-569.
23. Komatsu N., Kawamata N., Takeuchi S., Yin D., Chien W., Miller C.W., Koeffler H.P. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Rep. 2006, 15:187-191.
24. LeBoeuf M., Terrell A., Trivedi S., Sinha S., Epstein J.A., Olson E.N., Morrisey E.E., Millar S.E. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev. Cell 2010, 19:807-818.
25. Mahalingam D., Medina E.C., Esquivel J.A., Espitia C.M., Smith S., Oberheu K., Swords R., Kelly K.R., Mita M.M., Mita A.C., Carew J.S., Giles F.J., Nawrocki S.T. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 2010, 16:141-153.
26. Makin G., Hickman J.A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 2000, 301:143-152.
27. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
28. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92:1210-1216.
29. Motley R., Kersey P., Lawrence C., British Association of D., British Association of Plastic Surgeons Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br. J. Dermatol. 2002, 146:18-25.
30. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
31. Ramaswamy B., Fiskus W., Cohen B., Pellegrino C., Hershman D.L., Chuang E., Luu T., Somlo G., Goetz M., Swaby R., Shapiro C.L., Stearns V., Christos P., Espinoza-Delgado I., Bhalla K., Sparano J.A. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res. Treat. 2011, 3:1063-1067.
32. Ramsey M.R., He L., Forster N., Ory B., Ellisen L.W. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 2011, 71:4373-4379.
33. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003, 2:1273-1284.
34. Singh T., Chaudhary S.C., Kapur P., Weng Z., Elmets C.A., Kopelovich L., Athar M. Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis. Photochem. Photobiol. 2012, 5:1141-1148.
35. Society, American Chemical Cancer facts and figures. Serial publications: Annual Report; Cancer Facts and Figures (booklet), annual 2011, Atlanta,GA, http://www.cancer.org/acs/groups/content@epidemiologysurveilance/documents/document/acspc-029771.pdf via the internet: accessed 23rd Jan 2012.
36. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
37. Uehara N., Kanematsu S., Miki H., Yoshizawa K., Tsubura A. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett. 2012, 315:112-121.
38. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
39. Wedel S., Hudak L., Seibel J.M., Makarevic J., Juengel E., Tsaur I., Wiesner C., Haferkamp A., Blaheta R.A. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin. Exp. Metastasis 2011, 28:479-491.
40. Xargay-Torrent S., Lopez-Guerra M., Saborit-Villarroya I., Rosich L., Campo E., Roué G., Colomer D. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin. Cancer Res. 2011, 17:3956-3968.
41. Yan N., Shi Y. Mechanisms of apoptosis through structural biology. Annu. Rev. Cell Dev. Biol. 2005, 21:35-56.
42. Zwald F.O., Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J. Am. Acad. Dermatol. 2011, 65:253-261.